|Bid||20.86 x 4000|
|Ask||21.35 x 3000|
|Day's range||20.60 - 21.39|
|52-week range||16.63 - 39.59|
|Beta (3Y monthly)||2.05|
|PE ratio (TTM)||344.26|
|Earnings date||4 Nov 2019 - 8 Nov 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||26.57|
Pfizer (PFE) sales in the second half may take a hit due to business development activity, incremental currency headwinds and potentially lower sales of key drugs Prevnar and Xeljanz.
Credit Suisse Group AG has brought on three new senior investment bankers as it continues to build out its healthcare investment banking division, according to an internal memo reviewed by Reuters. The three managing directors, Andrew Singer, Lorenzo Paoletti and Liav Abraham, will join Credit Suisse this fall, the memo said.
Acorda's (ACOR) lead MS drug Ampyra is hit by generic rivalry in the United States, which is hurting the company's top line. Parkinson's disease drug Inbrija can be an ideal replacement.
Despite lower demand hurting volumes of Enbrel, it remains the largest drug for Amgen (AMGN). A district court decision prevents Novartis from launching Erelzi, its biosimilar version of Enbrel.
As the Oct. 31 deadline for Britain to leave the European Union approaches, health professionals are warning that shortages of some medicines could worsen in Europe in the event of a no-deal Brexit. Britain's food and drink lobby warned last week that the country would experience shortages of some fresh foods if there is a disorderly no-deal Brexit.
Acorda (ACOR) posts narrower-than-expected loss while revenues top estimates in the second quarter. Inbrija delivers a solid start with sales rising sequentially.
Amgen (AMGN) beats estimates for earnings and sales in the second quarter. Higher demand for new growth drivers was offset by the erosion of mature brands from brand/biosimilar competition.
U.S. stocks slipped on Tuesday after a warning from President Donald Trump to China pressured technology shares, while investors looked to an expected interest rate cut at the conclusion of the Federal Reserve's monetary policy meeting. The three major U.S. stock indexes were in the red, pressured by consumer discretionary and technology stocks.
The drugmaker in a regulatory filing on Monday disclosed that it had reached an agreement-in-principle with the SEC's enforcement staff to resolve the investigation that dated back to 2016. Mylan said it will neither admit nor deny wrongdoing as part of the accord. The EpiPen, which Mylan acquired in 2007, is a handheld device that treats life-threatening allergic reactions by automatically injecting a dose of epinephrine.